Karyopharm completes enrollment in Phase 3 Sentry trial

Karyopharm (KPTI) Therapeutics announced that it has completed enrollment in the Phase 3 SENTRY trial, which is evaluating selinexor in combination with ruxolitinib in JAKi-naive myelofibrosis patients. “We are excited to announce that we have completed enrollment of our Phase 3 SENTRY trial and look forward to sharing top-line data from this pivotal trial in March 2026,” said Richard Paulson, President and CEO. “Selinexor plus ruxolitinib has the potential to be the first combination therapy approved for the treatment of myelofibrosis, depending on the outcome of the data. By combining selinexor with the current standard of care, we believe we have the potential to redefine the way people living with myelofibrosis are treated.” SENTRY is a Phase 3 clinical trial evaluating a once-weekly dose of 60 mg of selinexor in combination with ruxolitinib compared to placebo plus ruxolitinib in JAKi-naive myelofibrosis patients with platelet counts greater than100 x 109/L. Patients are randomized 2-to-1 to the selinexor arm. The co-primary endpoints for this trial are spleen volume response rate greater than or equal to 35% at week 24 and the average change in absolute total symptom score over 24 weeks relative to baseline. The Phase 3 trial enrolled 353 patients.